InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative anti-inflammatory therapeutics. Founded in 2007, the company's core mission is to address life-threatening or debilitating inflammatory diseases with high unmet medical needs by applying its proprietary anti-C5a and anti-C5aR technologies. Headquartered in Jena, Germany, InflaRx also maintains offices in Munich, Germany, and Ann Arbor, Michigan, USA.

The company's pipeline is centered on potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. Key product candidates include vilobelimab, an intravenously delivered first-in-class anti-C5a monoclonal antibody, and izicopan (also known as INF904), an orally administered small molecule inhibitor of the C5a receptor. Vilobelimab has received Emergency Use Authorization (EUA) in the US for critically ill COVID-19 patients and marketing authorization in the EU for SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS). Izicopan is currently in development for conditions such as hidradenitis suppurativa and chronic spontaneous urticaria.

Recent developments for InflaRx include regaining compliance with Nasdaq's minimum bid price requirement in April 2026. The company also reported new mechanistic data for Izicopan in April 2026 and highlighted clinical activity of Vilobelimab in Pyoderma Gangrenosum in March 2026. The leadership team is headed by CEO and Founder Prof. Dr. Niels C. Riedemann, with Prof. Renfeng Guo serving as CSO and Founder, and Dr. Thomas Taapken as CFO.